Celyad gets the go-ahead to re­sume CAR-T tri­al for col­orec­tal can­cer as FDA lifts hold

Four months ago, the FDA placed a clin­i­cal hold on Celyad’s CAR-T tri­al for col­orec­tal can­cer af­ter two pa­tients died dur­ing the study. Reg­u­la­tors have now lift­ed the hold, al­low­ing the Bel­gian com­pa­ny’s tri­al to set sail once again.

On Feb. 28, Celyad an­nounced that it had “vol­un­tar­i­ly paused” the tri­al of its off-the-shelf CAR-T in com­bi­na­tion with Mer­ck’s PD-1 in­hibitor Keytru­da as it in­ves­ti­gat­ed the deaths. Both pa­tients had “pre­sent­ed with sim­i­lar pul­monary find­ings,” the com­pa­ny added with­out fur­ther ex­pla­na­tion. The FDA im­posed the hold short­ly af­ter the com­pa­ny’s an­nounce­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER